Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation by circulating serum factors in human glomerulonephritis.

S Meri

    Clinical and Experimental Immunology
    |February 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains.

    Molecular immunology·2022
    Same author

    Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1.

    Nature communications·2021
    Same author

    Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study.

    BJOG : an international journal of obstetrics and gynaecology·2021
    Same author

    Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.

    The British journal of dermatology·2019
    Same author

    Distribution of exogenous complement factor H in mice in vivo.

    Scandinavian journal of immunology·2018
    Same author

    Intracellular complement activation-An alarm raising mechanism?

    Seminars in immunology·2018
    Same journal

    The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

    Clinical and experimental immunology·2026
    Same journal

    PD-1 Engagement and Circulating Th17 Effector Activity During Secukinumab Treatment in Plaque Psoriasis.

    Clinical and experimental immunology·2026
    Same journal

    Henoch-Schoenlein purpura (HSP) like lesions in IL12RB1 and IL12B defects - A multi-centric experience from India.

    Clinical and experimental immunology·2026
    Same journal

    Case Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodies.

    Clinical and experimental immunology·2026
    Same journal

    Deleterious germline CARD11 gain-of-function variants alter human B-cell and CD4+ T-cell differentiation and function.

    Clinical and experimental immunology·2026
    Same journal

    Clinical, genetic, and functional characterization of novel NFKB1 variants in Chinese patients with primary immunodeficiency.

    Clinical and experimental immunology·2026
    See all related articles

    Researchers identified diverse complement C3 activating factors in glomerulonephritis (GN) patient sera. These factors, including C3 nephritic factor and rheumatoid factors, indicate varied pathogenic mechanisms in GN.

    Area of Science:

    • Immunology
    • Nephrology
    • Complement System Biology

    Background:

    • Glomerulonephritis (GN) involves complex immune dysregulation.
    • The complement system, particularly C3 conversion, plays a critical role in GN pathogenesis.
    • Identifying specific complement-activating factors can elucidate disease mechanisms.

    Purpose of the Study:

    • To investigate and characterize factors inducing C3 conversion in normal human serum (NHS) from glomerulonephritis (GN) patients.
    • To categorize these C3-activating factors based on their properties and association with specific GN types.
    • To explore the potential role of these factors in the pathogenetic mechanisms of GN.

    Main Methods:

    • Analysis of patient sera for C3 conversion induction in NHS.

    Related Experiment Videos

  • Characterization of C3-activating factors using immunochemical analysis and gel filtration.
  • Assessment of factor properties including heat lability and association with immune complexes.

    • Main Results:

    • Nine GN patients exhibited factors inducing ≥20% C3 conversion in NHS.
    • Three cases showed C3 nephritic factor (IgG autoantibody) stabilizing the alternative pathway C3 convertase.
    • One case revealed a monoclonal IgM kappa rheumatoid factor causing C3 activation, associated with cryoprecipitable IgM-IgG complexes.
    • Five cases had unknown C-activating factors, with four being heat-labile and linked to post-streptococcal GN.

    Conclusions:

    • Heterogeneous C3-activating factors are present in GN patient sera.
    • These factors, distinct from classical immune complexes, include C3 nephritic factor and rheumatoid factors.
    • The identified factors suggest diverse pathogenetic mechanisms underlying different forms of GN.